RedHill Biopharma (RDHL) Cash from Operations (2016 - 2022)
RedHill Biopharma has reported Cash from Operations over the past 11 years, most recently at 2421000.0 for Q4 2022.
- Quarterly Cash from Operations rose 83.71% to 2421000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was 29185000.0 through Dec 2022, up 55.13% year-over-year, with the annual reading at 7191000.0 for FY2025, 19.52% up from the prior year.
- Cash from Operations was 2421000.0 for Q4 2022 at RedHill Biopharma, up from 6028000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 2421000.0 in Q4 2022 and troughed at 19025000.0 in Q3 2021.
- The 5-year median for Cash from Operations is 9974500.0 (2018), against an average of 10848650.0.
- Year-over-year, Cash from Operations tumbled 107.45% in 2021 and then surged 83.71% in 2022.
- A 5-year view of Cash from Operations shows it stood at 8194000.0 in 2018, then plummeted by 69.26% to 13869000.0 in 2019, then increased by 8.39% to 12705000.0 in 2020, then decreased by 16.95% to 14859000.0 in 2021, then surged by 83.71% to 2421000.0 in 2022.
- Per Business Quant, the three most recent readings for RDHL's Cash from Operations are 2421000.0 (Q4 2022), 6028000.0 (Q3 2022), and 16581000.0 (Q2 2022).